Reto Naef

USPTO Granted Patents = 13 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 99(Granted Patents)

Location History:

Rheinfelden, CH (1990 - 2024)
Schlieren, CH (2022 - 2024)

Company Filing History:

Years Active: 1990-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12351585 - 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof (2025-07-08),

2. 11905293 - Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof (2024-02-20),

3. 11897890 - 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof (2024-02-13),

4. 11242347 - 2-phenyl-3,4-dihydropyrrolo[2,1-Ff] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof (2022-02-08),

5. 11155558 - Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof (2021-10-26),

6. 10570137 - 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof (2020-02-25),

7. 7019136 - 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors (2006-03-28),

8. 5925649 - Ascomycins (1999-07-20),

9. 5852005 - Tetracyclic triterpenes (1998-12-22),

10. 5747506 - Isoquinoline compounds, compositions containing them and their (1998-05-05),

11. 5643870 - O-acylated cyclosporins (1997-07-01),

12. 5177085 - Dihydro-isoquinoline derivatives, processes for their production, (1993-01-05),

13. 4980359 - Isoquinoline derivatives and their use (1990-12-25),

Title: Reto Naef: Innovator in Pharmaceutical Chemistry

Introduction

Reto Naef is a distinguished inventor based in Rheinfelden, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as phosphodiesterase inhibitors. With a total of 13 patents to his name, Naef's work has the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents are two notable inventions. The first is titled "2-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof." This invention relates to specific compounds that can be utilized in treating diseases alleviated by the inhibition of PDE-5. The second patent, "Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof," also focuses on compounds that can aid in similar therapeutic applications.

Career Highlights

Reto Naef has worked with prominent companies in the pharmaceutical industry, including Topadur Pharma AG and Novartis AG. His experience in these organizations has allowed him to refine his expertise and contribute to innovative solutions in drug development.

Collaborations

Throughout his career, Naef has collaborated with notable colleagues such as Hermann Tenor and Johann Jakob Boelsterli. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Reto Naef's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.